Hutchmed (China)
HCM
13.22
-0.23
-1.71%
Hutchmed (China)
US · HCM
#2639 by market cap
Listed 2016
13.22
-0.23
-1.71%
Periodic snapshot; not a real-time feed.
· 2026-11-20 16:10
Recent news
-
Rating change
Hutchmed (00013.HK): Positive Phase III Data for Savolitinib; Expansion of Indications Domestically and Internationally Expected to Unlock Growth PotentialGuangfa Securities · 2026/10/29
-
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic AnemiaGlobeNewswire · 2026/11/5
-
Rating change
Hutchmed (0013.HK) Savolitinib: Two Phase III Trials Succeed at ESMO, Overseas Commercialization Prospects Look PromisingHuatai Securities · 2026/10/27
-
Company notice
HUTCHMED: Monthly Return of Equity Issuer on Movements in Securities for the month ended October 31, 2026HKEX · 2026/11/2
-
Hutchmed (0013.HK): Two sets of Phase III data validate the potential of savolitinib in lung cancer treatment, paving the way for its global blockbuster trajectory.BOC International · 2026/11/10
-
Company notice
HUTCHMED: VOLUNTARY ANNOUNCEMENT - Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung CancerHKEX · 2026/10/27
-
Rating change
BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Raises Target Price to $18Market Newswire · 2026/9/21
-
Hong Kong Stock Market Update | Hutchmed (00013) rises over 4% as surufatinib receives FDA orphan drug designation for the treatment of autoimmune hemolytic anemiaZhitong Finance · 2026/11/5
-
Rating change
HUTCHMED (00013.HK): Savolitinib U.S. Marketing Application; ESMO Announces SAFFRON ResultsCICC · 2026/10/27
-
Rating change
Hutchmed (0013.HK): Savolitinib Shines in Two Phase III Studies at the 2026 ESMO CongressCitic Securities · 2026/10/30
-
Company notice
HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune ThrombocytopeniaHKEX · 2026/10/29
-
Rating change
Hutchmed (00013.HK) Update: Dual Late-Breaking Abstracts Shine at ESMO as Savolitinib Accelerates ExpansionOriental Securities · 2026/10/30
-
Hutchmed (00013.HK): Sovleplenib Receives FDA Orphan Drug Designation for the Treatment of Autoimmune Hemolytic AnemiaGelonghui Finance · 2026/11/5
-
Company notice
HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS plus TAGRISSO in MET-Driven EGFR-Mutated Lung Cancer in Europe and JapanHKEX · 2026/11/2
-
Company notice
HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic AnemiaHKEX · 2026/11/5
-
Rating change
CICC: Maintains target price of HK$28 for Hutchmed (00013); rating remains "Outperform"Zhitong Finance · 2026/10/28
-
Rating change
BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Maintains Target Price $18Market Newswire · 2026/10/27
-
Rating change
Hutchmed (00013.HK): Clear survival benefit demonstrated with savolitinib combination regimen; precision medicine strategy shifts toward first-line treatmentSoochow Securities · 2026/10/28
-
Rating change
Hutchmed (00013.HK): Savolitinib Phase III trials globally validate the value of precision therapy targeting EGFR/cMETOpen Source Securities · 2026/10/28
-
[Major Banks] Citi Raises Hutchmed's (00013.HK) Target Price to HK$43.2, Upgrades Revenue and EPS Forecasts, Names It New Top PickAASTOCKS · 2026/11/6
-
Rating change
Hutchmed (00013.HK): The SAFFRON global Phase III study of savolitinib has yielded positive results, potentially accelerating its global regulatory submissions.Dongwu Securities · 2026/8/18
-
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune ThrombocytopeniaGlobeNewswire · 2026/10/29
-
Rating change
Hutchmed (0013.HK): ATTC licensing to GSK clarifies overseas expansion pathHuatai Securities · 2026/9/3
-
Company notice
HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of MedicineHKEX · 2026/10/26
-
Rating change
CICC: Maintains "Outperform" rating for Hutchmed (00013), raises target price to HK$28Zhitong Finance · 2026/9/8
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 16:10:04 · For reference only, not investment advice and not tailored to your situation.
Hutchmed (China) discussion 0 comments